24 October 2022

dorsaVi partners with Medtronic to develop new technology

- **dorsaVi and Medtronic have developed a new sensor application to assess movement quality for patients with spinal conditions**
- **In this partnership, dorsaVi's leading wearable sensor technology and custom-built AI algorithms leverages Medtronic's world-class expertise medical treatment technologies**
- **Beta testing has commenced in the United States at a clinical site and dorsaVi will be working closely with the site to monitor progress**
- **dorsaVi has further extended its agreement with Medtronic for 9 months, worth an additional ~US$129k**
- **Development of the wearable sensor application follows a long relationship with Medtronic, which is a continued source of new revenue for dorsaVi**
- **This long-term agreement has been recently extended to optimize the technology for complex applications, which represents an additional source of new revenue for dorsaVi**
- **dorsaVi is excited to continue co-developing the product as it heads toward commercialisation**

Melbourne, Australia, 24 October 2022: dorsaVi (ASX:DVL) (dorsaVi or the Company) is pleased to provide an update in relation to the ongoing project and strategic partnership with Medtronic.

dorsaVi and Medtronic have collaborated to successfully develop the first beta version of a new sensor application for the assessment of movement quality in patients with various spinal conditions. DorsaVi's wearable sensor technology is intended to make it possible to drive greater spinal diagnostic insights via wearable patient movement sensors.

Beta testing is now underway at a clinical site in the United States, which represents an important partnership milestone. DorsaVi is working closely with the site to monitor progress and assist with any clinical testing processes and data interpretation.

Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, commented:

> *"I am delighted to provide an update on the ongoing project with Medtronic and announce the release of the beta sensor application for use in clinical studies. The project is the result of over one and a half years of collaboration between dorsaVi and Medtronic where our cutting-edge sensor technology and proprietary AI algorithms have helped make the project possible. With the initial development phase complete and beta testing underway, we are proud of the milestones we have achieved to date, and look forward to progressing our relationship with Medtronic as the project evolves. "*

This update has been authorised for lodgement to the ASX by the Company's Disclosure Committee.

– ENDS –

For further information about dorsaVi, please contact:

Company	Investors
Andrew Ronchi	Dean Dribbin
Chief Executive Officer	Vesparum Capital
+61 417 882 267	+61 3 8582 4800
Email: ar@dorsavi.com	Email: dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX listed company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.

- **Clinical**: dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com